![](https://hsomm.gr/wp-content/uploads/2018/12/artcle-national-150x150.jpg)
Histopathological Study of Mucormycosis in Post COVID-19 Patients and Factors Affecting it in a Tertiary Care Hospital – PMC (nih.gov)
8 Ιουλίου, 2024![](https://hsomm.gr/wp-content/uploads/2024/07/article-journal-of-150x150.jpg)
Colonic Mucormycosis in Fistulizing Crohn’s Disease
8 Ιουλίου, 2024Cutaneous Mucormycosis of the Eyelid Treated With Subcutaneous Liposomal Amphotericin B Injections
Cutaneous mucormycosis is a rare, opportunistic fungal infection that typically affects immunocompromised hosts. Current treatment consists of systemic antifungal therapy, surgical debridement, and when applicable, restoration of immune function. Despite intervention, the morbidity and mortality of invasive fungal disease remains high. There are few reports of primary or secondary cutaneous mucormycosis involving the ocular adnexa. The authors describe the course of 2 children with cutaneous mucormycosis of the eyelid treated with subcutaneous liposomal amphotericin B (LAmB) injections (3.5 mg/ml) in an off-label application as an adjunct to debridement and systemic antifungal therapy… read more